Treatment options for Adrenocortical carcinoma mapped across 6 countries — covering chemotherapy, clinical trials, immunotherapy and radiation — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedSolid tumorLast checked June 2026
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
United States
Mitotane (Lysodren)[1]FDA-approvedFunctional versus nonfunctional hormonal status is clinically relevant; no genomic biomarker required by fetched U.S. label; Inoperable functional or nonfunctional ACC. · Label indication does not establish payer coverage, treatment suitability, or dosing for a specific patient. Label includes major safety updates and monitoring/handling precautions. Confidence/conflicts: High for U.S. labeled indication.
European Union
Mitotane (Lysodren)[2]EMA authorisedFunctional hormone-producing status affects symptom benefit; no genomic biomarker required by fetched EMA source; Advanced unresectable, metastatic, or relapsed ACC; symptom treatment context per EMA wording. · EMA central authorisation does not establish member-state reimbursement, local specialist access, or individual eligibility. EMA notes limited evidence for some uses and the need for blood-level monitoring. Confidence/conflicts: High for EU authorised indication; national reimbursement remains unverified.
United Kingdom
Mitotane (Lysodren), alone or with other chemotherapy drugs[3]ApprovedNo biomarker required by fetched UK source; Unresectable, relapsed, or metastatic ACC. · Cancer Research UK is a patient/professional cancer information charity, not MHRA/NICE. Exact UK licensing, commissioning, and local formulary status require separate regulator/NHS source verification. Confidence/conflicts: Medium-high for UK treatment-information context; exact MHRA/NICE status remains an active gap.
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked June 2026.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
OsilodrostatClinical trial · NCT02468193Clinical trialTrial only (registry)Japan · Hormone-producing Cushing syndrome context; no genomic biomarker required by fetched registry record; Cushing syndrome and related adrenal disease context including adrenal carcinoma. · This is not an ACC-directed anticancer trial; it is a hormonal/symptom-control context that includes adrenal carcinoma. Registry listing does not establish PMDA approval, reimbursement, routine access, or individual eligibility. Confidence/conflicts: Medium for Japan ACC-related supportive/hormonal trial context; low for Japan tumor-directed ACC treatment availability. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab plus lenvatinib; real-world adrenal disease registry/cohort management studiesClinical trial · NCT05036434Clinical trialTrial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced adrenal cortical carcinoma for pembrolizumab/lenvatinib; adrenal disease evidence-generation/cohort contexts including ACC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Observational adrenal disease records are not treatment access records. Confidence/conflicts: Medium-high for Korea registry-listed ACC trial/cohort activity; routine access unverified. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
Is complete surgical resection feasible at an ACC-experienced center?
Is mitotane being discussed as adjuvant, unresectable, metastatic, or symptom-control therapy?
Are hormone-producing symptoms being managed alongside cancer-directed treatment?
Is the ACC inoperable, functional, or nonfunctional under the U.S. label indication?